500 related articles for article (PubMed ID: 28865475)
21. Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15D instruments.
Kontodimopoulos N; Aletras VH; Paliouras D; Niakas D
Value Health; 2009; 12(8):1151-7. PubMed ID: 19558372
[TBL] [Abstract][Full Text] [Related]
22. Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms.
Meregaglia M; Tarricone R
Pharmacoecon Open; 2022 Jul; 6(4):595-603. PubMed ID: 35182375
[TBL] [Abstract][Full Text] [Related]
23. A systematic review of health state utility values in Thai cancer patients.
Kangwanrattanakul K
Expert Rev Pharmacoecon Outcomes Res; 2022 Dec; 22(8):1171-1186. PubMed ID: 36084926
[TBL] [Abstract][Full Text] [Related]
24. Differences in utility elicitation methods in cardiovascular disease: a systematic review.
Blieden Betts M; Gandra SR; Cheng LI; Szatkowski A; Toth PP
J Med Econ; 2018 Jan; 21(1):74-84. PubMed ID: 28899233
[TBL] [Abstract][Full Text] [Related]
25. Systematic Review of the Psychometric Performance of Generic Childhood Multi-attribute Utility Instruments.
Kwon J; Smith S; Raghunandan R; Howell M; Huynh E; Kim S; Bentley T; Roberts N; Lancsar E; Howard K; Wong G; Craig J; Petrou S
Appl Health Econ Health Policy; 2023 Jul; 21(4):559-584. PubMed ID: 37133712
[TBL] [Abstract][Full Text] [Related]
26. Critical appraisal of health-state utility values used in breast cancer-related cost-utility analyses.
Nerich V; Saing S; Gamper EM; Holzner B; Pivot X; Viney R; Kemmler G
Breast Cancer Res Treat; 2017 Aug; 164(3):527-536. PubMed ID: 28497177
[TBL] [Abstract][Full Text] [Related]
27. The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.
Meregaglia M; Nicod E; Drummond M
Eur J Health Econ; 2023 Sep; 24(7):1151-1216. PubMed ID: 36335234
[TBL] [Abstract][Full Text] [Related]
28. Health state utility values measured using the EuroQol 5-dimensions questionnaire in adults with chronic hepatitis C: a systematic literature review and meta-analysis.
Buchanan-Hughes AM; Buti M; Hanman K; Langford B; Wright M; Eddowes LA
Qual Life Res; 2019 Feb; 28(2):297-319. PubMed ID: 30225787
[TBL] [Abstract][Full Text] [Related]
29. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: an online database and application of the MAPS statement.
Dakin H; Abel L; Burns R; Yang Y
Health Qual Life Outcomes; 2018 Feb; 16(1):31. PubMed ID: 29433510
[TBL] [Abstract][Full Text] [Related]
30. A Head-to-Head Comparison of the EQ-5D-5L and AQoL-8D Multi-Attribute Utility Instruments in Patients Who Have Previously Undergone Bariatric Surgery.
Campbell JA; Palmer AJ; Venn A; Sharman M; Otahal P; Neil A
Patient; 2016 Aug; 9(4):311-22. PubMed ID: 26841910
[TBL] [Abstract][Full Text] [Related]
31. A review of health utilities across conditions common in paediatric and adult populations.
Tarride JE; Burke N; Bischof M; Hopkins RB; Goeree L; Campbell K; Xie F; O'Reilly D; Goeree R
Health Qual Life Outcomes; 2010 Jan; 8():12. PubMed ID: 20105304
[TBL] [Abstract][Full Text] [Related]
32. Health state utility values (QALY weights) for Huntington's disease: an analysis of data from the European Huntington's Disease Network (EHDN).
Hawton A; Green C; Goodwin E; Harrower T
Eur J Health Econ; 2019 Dec; 20(9):1335-1347. PubMed ID: 31410669
[TBL] [Abstract][Full Text] [Related]
33. Construct Validity of the EuroQoL-5 Dimension and the Health Utilities Index in Head and Neck Cancer.
Noel CW; Keshavarzi S; Forner D; Stephens RF; Watson E; Monteiro E; Hosni A; Hansen A; Goldstein DP; de Almeida JR
Otolaryngol Head Neck Surg; 2022 May; 166(5):877-885. PubMed ID: 34311628
[TBL] [Abstract][Full Text] [Related]
34. Systematic review of health state utility values for acute myeloid leukemia.
Forsythe A; Brandt PS; Dolph M; Patel S; Rabe APJ; Tremblay G
Clinicoecon Outcomes Res; 2018; 10():83-92. PubMed ID: 29416365
[TBL] [Abstract][Full Text] [Related]
35. Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review.
Paracha N; Thuresson PO; Moreno SG; MacGilchrist KS
Expert Rev Pharmacoecon Outcomes Res; 2016 Oct; 16(5):549-559. PubMed ID: 27574879
[TBL] [Abstract][Full Text] [Related]
36. A review of health-utility data for osteoarthritis: implications for clinical trial-based evaluation.
Ruchlin HS; Insinga RP
Pharmacoeconomics; 2008; 26(11):925-35. PubMed ID: 18850762
[TBL] [Abstract][Full Text] [Related]
37. A systematic review of health state utility values for thyroid cancer.
Houten R; Fleeman N; Kotas E; Boland A; Lambe T; Duarte R
Qual Life Res; 2021 Mar; 30(3):675-702. PubMed ID: 33098494
[TBL] [Abstract][Full Text] [Related]
38. A structured review of health utility measures and elicitation in advanced/metastatic breast cancer.
Hao Y; Wolfram V; Cook J
Clinicoecon Outcomes Res; 2016; 8():293-303. PubMed ID: 27382319
[TBL] [Abstract][Full Text] [Related]
39. Comparing EQ-5D scores for comorbid health conditions estimated using 5 different methods.
Ara R; Brazier J
Med Care; 2012 May; 50(5):452-9. PubMed ID: 22002647
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
